Success Stories: EB-1A Petition Was Approved for Assistant Research Scientist in the Field of Plant Physiology in the State of West Virginia

Client’s Testimonial:

Thank you very much for your uncompromised professional support in my EB-1A petition. Your confidence in my case is evident from your refund policy. […] I have already informed a couple of my friends about your organization. I will do the same in the future.

On July 14^th, 2014, We Received an EB-1A Alien of Extraordinary Ability Approval for a Assistant Research Scientistin the Field of Plant Physiology (Approval Notice)

General Field: Plant Physiology

Position at the Time of Case Filing: Assistant Research Scientist

Country of Origin: India

Service Center: Texas Service Center (TSC)

State of Residence at the Time of Filing: West Virginia

Approval Notice Date: July 14, 2014

Processing Time: 4 Months, 7 Days

Case Summary:

For this EB-1A Alien of Extraordinary Ability case, we had the privilege of working with an Assistant Research Scientist, who has made substantial contributions and garnered international acclaim in the field of Plant Physiology. Our client has pioneered studies on nutraceuticals and nutraceutical genomics to develop anticancer, anti-diabetic, analgesic, and fat-burning herbal compounds. In addressing some of our nation’s most pressing medical concerns, he has improved the construction and utilization of medical implants, he has fostered a greater insight into the effects of anti-cancer chemicals, and he has adapted the supplementation of selenium-rich foods for nutritional regimes of cancer patients. The major significance of his work was endorsed by an independent recommender, who stated, “[Client] has experience, knowledge and abilities that set him apart from others in agricultural research. His combination of plant physiology, food science, and practical knowledge of agriculture makes him unique, and he stands out above the average person in the research area. His current research on nutraceuticals, especially his remarkable research in anti-diabetic compounds in crops, is imperative to ensure the optimization of human health through diet.”Our client’s profound understanding of plant physiology and biomedical nanotechnology has revolutionized the methodologies that are currently used for oncological studies. His contributions have resulted in novel medical devices that help prevent tumor corrosion, and he has bridged the gap between herbal and modern medicine for the development of new cancer therapeutics. The originality of his work has culminated in the authorship of numerous conference proceedings, 10 peer-reviewed scientific manuscripts that were published in the top journals of his field, and several international patents. At the time of filing his case, his publications had been cited 155 times by researchers worldwide, demonstrating the global scientific community’s heavy reliance upon his work. Furthermore, his work has been presented and discussed at internationally renowned conferences. Additionally, our client has been invited to judge the work of his colleagues and other forerunners in his field, and he has served as an editorial board member for 3 highly distinguished, internationally circulated journals related to the field of Plant Physiology. In total, he has reviewed 8 manuscripts thus far. In demonstrating the extraordinary ability of our client and international acclaim for his research, we were able to prove that he has risen to the very top of his field of endeavor. With the extensive and thorough documentation that we provided, we were met with success when his EB-1A petition was expeditiously approved in 4 months and 7 days.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 47,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our approved cases grew from 600 in 2013 to over 47,000 in 2023.